AAPA members, login now to find more great articles. Not an AAPA member? Join today!

Institutional members access full text with Ovid®

Share this article on:

Mirabegron: A new option in treating overactive bladder

Turpen, Heidi Camus PA-C; Zimmern, Philippe E. MD

Journal of the American Academy of Physician Assistants: November 2015 - Volume 28 - Issue 11 - p 16–18
doi: 10.1097/01.JAA.0000472558.50124.7e
Pharmacology Consult

ABSTRACT Antimuscarinic medications have long been the mainstay of drug treatment for overactive bladder. This article describes mirabegron, one of a new class of agents that relaxes the detrusor muscle directly via a beta3 adrenoceptor agonist. Mirabegron's efficacy on frequency, urgency, and urge incontinence was tested in several trials before its wide clinical introduction. However, caution is still needed as data are lacking on the drug's efficacy and safety in frail older adults and for long-term therapy.

Heidi Camus Turpen practices at the University of Texas Southwestern Medical Center in Dallas, Tex. Philippe E. Zimmern is a professor of urology at the University of Texas Southwestern Medical Center. The authors have disclosed no potential conflicts of interest, financial or otherwise.

Mary Lou Brubaker, PharmD, PA-C, department editor

Copyright © 2015 American Academy of Physician Assistants
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website